Advances in Therapy

, Volume 36, Issue 1, pp 1–18 | Cite as

Silodosin: An Update on Efficacy, Safety and Clinical Indications in Urology

  • Luca VillaEmail author
  • Paolo Capogrosso
  • Umberto Capitanio
  • Alberto Martini
  • Alberto Briganti
  • Andrea Salonia
  • Francesco Montorsi



Silodosin determines smooth muscle relaxation in bladder and prostate tissues, increases bladder blood flow in conditions of chronic bladder ischemia and regulates the activity of transcriptional factors responsible for stromal growth and prostate hyperplasia. Phase III trials have already demonstrated the efficacy and safety of silodosin in the treatment of patients bothered by lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).


We aimed to describe the rationality for the use of silodosin and to summarize the current literature on the use of Silodosin for the treatment of LUTS.


PubMed and Web of Science were queried with the terms: ‘silodosin’ in combination (AND) with the terms ‘lower urinary tract symptoms’, ‘LUTS’, ‘pathophysiology’, ‘symptoms’ OR therapy’. Studies published in the last 10 years (2007–2017) in adults and core clinical journals in English were included.


Silodosin 8 mg once-daily was superior to placebo in improving IPSS total score, voiding subscore, storage subscore and QoL score, and at least as effective as tamsulosin 0.4 mg once-daily in all the efficacy analyses. In addition, studies assessing the effect on urodynamic parameters showed that silodosin determined a higher improvement in the bladder outlet obstruction index compared to other alpha1 adrenergic receptor antagonists. Concerning the safety profile, long-term data (after 9 months of treatment) confirmed the limited effect of silodosin on the cardiovascular and gastrointestinal systems. Although ejaculatory disorders represented the main complaint of patients taking silodosin, the discontinuation rate due to this condition remained low even in a long-term follow-up study (7.5%). Encouraging findings showed that silodosin may be administered as a medical expulsive therapy for promoting spontaneous stone passage of distal ureteral stones < 10 mm, to relieve LUTS in patients who underwent prostate cancer brachytherapy and to increase the likelihood of successful trials without a catheter in patients experiencing acute urinary retention.


Silodosin is one of the drugs approved for the treatment of BPH, being highly effective in improving not only LUTS but also urodynamic parameter impairments secondary to BPH. Moreover, it has shown efficacy as medical expulsive therapy for distal ureteral stones in previous prospective randomized trials.


Sponsorship for this study and article processing charges were funded by Recordati.


Acute urinary retention Benign prostatic hyperplasia BPH Brachytherapy Lower urinary tract symptoms LUTS Silodosin Ureteral stone 




Sponsorship for this study and article processing charges were funded by Recordati. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.


All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.


Luca Villa has received research support, consultancy and lecturer honoraria in the field of α1-adrenoceptors from Recordati. Umberto Capitanio has received research support, consultancy and lecturer honoraria in the field of α1-adrenoceptors from Recordati. Andrea Salonia has received research support, consultancy and lecturer honoraria in the field of α1-adrenoceptors from Recordati. Francesco Montorsi has received research support, consultancy and lecturer honoraria in the field of α1-adrenoceptors from Recordati. Paolo Capogrosso, Alberto Martini and Alberto Briganti have nothing to disclose.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Issa MM, Fenter TC, Black L, et al. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care. 2006;12:S83–9.PubMedGoogle Scholar
  2. 2.
    Oelke M, Burger M, Castro-Diaz D, et al. Diagnosis and medical treatment of lower urinary tract symptoms in adult men: applying specialist guidelines in clinical practice. BJU Int. 2011;110:710–8.CrossRefGoogle Scholar
  3. 3.
    McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185:1793–803.CrossRefGoogle Scholar
  4. 4.
    De Nunzio C, Ahyai S, Autorino R, et al. Benign prostatic hyperplasia and lower urinary tract symptoms: research priorities. Eur Urol. 2011;60:1205–6.CrossRefGoogle Scholar
  5. 5.
    Parsons JK. Commentary on BPH and public health–have we lost the forest through the trees? J Urol. 2008;179:S81.CrossRefGoogle Scholar
  6. 6.
    Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate Suppl. 1990;3:1–7.CrossRefGoogle Scholar
  7. 7.
    Netto NR Jr, de Lima ML, Netto MR, D’Ancona CA. Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. Urology. 1999;53:314–6.CrossRefGoogle Scholar
  8. 8.
    Kupelian V, Wei JT, O’Leary MP, et al. Nocturia and quality of life: results from the Boston area community health survey. Eur Urol. 2012;61:78–84.CrossRefGoogle Scholar
  9. 9.
    Tikkinen KA, Johnson TM 2nd, Tammela TL, et al. Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol. 2010;57:488–96.CrossRefGoogle Scholar
  10. 10.
    Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67:1099–109.CrossRefGoogle Scholar
  11. 11.
    Tatemichi S, Kobayashi K, Maezawa A, et al. Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213) [article in Japanese]. Yakugaku Zasshi. 2006;126:209–16.PubMedGoogle Scholar
  12. 12.
    Akiyama K, Noto H, Nishizawa O, et al. Effect of KMD-3213, an alpha1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs. Int J Urol. 2001;8:177–83.CrossRefGoogle Scholar
  13. 13.
    Schilit S, Benzeroual KE. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Clin Ther. 2009;31:2489–502.CrossRefGoogle Scholar
  14. 14.
    Chapple CR, Montorsi F, Tammela TL, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59:342–52.CrossRefGoogle Scholar
  15. 15.
    Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181:2634–40.CrossRefGoogle Scholar
  16. 16.
    Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006;98:1019–24.CrossRefGoogle Scholar
  17. 17.
    Yu HJ, Lin AT, Yang SS, et al. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU Int. 2011;108:1843–8.CrossRefGoogle Scholar
  18. 18.
    Capitanio U, Salonia A, Briganti A, Montorsi F. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates. Int J Clin Pract. 2013;67:544–51.CrossRefGoogle Scholar
  19. 19.
    Nasu K, Moriyama N, Kawabe K, et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol. 1996;119:797–803.CrossRefGoogle Scholar
  20. 20.
    Shibata K, Foglar R, Horie K, et al. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol. 1995;48:250–8.PubMedGoogle Scholar
  21. 21.
    Martin DJ, Angel I, Arbilla S. Functional uroselectivity. Eur Urol. 1998;33(Suppl 2):12–8.CrossRefGoogle Scholar
  22. 22.
    Moriyama N, Akiyama K, Murata S. KMD-3213, a novel alpha1A-adrenoceptor antagonist, potently inhibits the functional alpha1-adrenoceptor in human prostate. Eur J Pharmacol. 1997;331:39–42.CrossRefGoogle Scholar
  23. 23.
    Goi Y, Tomiyama Y, Nomiya M, Sagawa K, Aikawa K, Yamaguchi O. Effects of silodosin, a selective α1A-adrenoceptor antagonist, on bladder blood flow and bladder function in a rat model of atherosclerosis induced chronic bladder ischemia without bladder outlet obstruction. J Urol. 2013;190:1116–22.CrossRefGoogle Scholar
  24. 24.
    Inoue S, Saito M, Tsounapi P, et al. Effect of silodosin on detrusor overactivity in the male spontaneously hypertensive rat. BJU Int. 2012;110:E118–24.CrossRefGoogle Scholar
  25. 25.
    Aizawa N, Watanabe D, Fukuhara H, et al. Inhibitory effects of silodosin on the bladder mechanosensitive afferent activities and their relation with bladder myogenic contractions in male rats with bladder outlet obstruction. Neurourol Urodyn. 2018. (Epub ahead of print).CrossRefPubMedGoogle Scholar
  26. 26.
    Hennenberg M, Strittmatter F, Beckmann C, et al. Silodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscle. PLoS ONE. 2012;7:e50904.CrossRefGoogle Scholar
  27. 27.
    Matsukawa Y, Gotoh M, Komatsu T, Funahashi Y, Sassa N. Hattori R Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study. J Urol. 2013;189:S117–21.CrossRefGoogle Scholar
  28. 28.
    Yamanishi T, Mizuno T, Tatsumiya K, et al. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourol Urodyn. 2010;29:558–62.PubMedGoogle Scholar
  29. 29.
    Fusco F, Creta M, Longo N, Persico F, Franco M, Mirone V. Silodosin 8 mg improves benign prostatic obstruction in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: results from an explorative clinical study. BMC Urol. 2018;18:12.CrossRefGoogle Scholar
  30. 30.
    Fusco F, Palmieri A, Ficarra V, et al. α1-Blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol. 2016;69:1091–101.CrossRefGoogle Scholar
  31. 31.
    Fusco F, Creta M, Imperatore V, et al. Benign prostatic obstruction relief in patients with lower urinary tract symptoms suggestive of benign prostatic enlargement undergoing endoscopic surgical procedures or therapy with alpha-blockers: a review of urodynamic studies. Adv Ther. 2017;34:773–83.CrossRefGoogle Scholar
  32. 32.
    Osman NI, Chapple CR, Tammela TL, Eisenhardt A, Oelke M. Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH. World J Urol. 2015;33:697–706.CrossRefGoogle Scholar
  33. 33.
    Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology. 2009;74:1318–22.CrossRefGoogle Scholar
  34. 34.
    Yamanishi T, Kaga K, Fuse M, Shibata C, Kamai T, Uchiyama T. Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: what are the factors for continuation or withdrawal? Int J Urol. 2015;22(12):1143–8.CrossRefGoogle Scholar
  35. 35.
    Ding H, Du W, Hou ZZ, Wang HZ, Wang ZP. Silodosin is effective for treatment of LUTS in men with BPH: a systematic review. Asian J Androl. 2013;15:121–8.CrossRefGoogle Scholar
  36. 36.
    Novara G, Tubaro A, Sanseverino R, et al. Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. World J Urol. 2013;31:997–1008.CrossRefGoogle Scholar
  37. 37.
    Novara G, Chapple CR, Montorsi F. A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). BJU Int. 2014;114:427–33.PubMedGoogle Scholar
  38. 38.
    Montorsi F, Gandaglia G, Chapple C, Cruz F, Desgrandchamps F, Llorente C. Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: a European phase IV clinical study (SiRE study). Int J Urol. 2016;23:572–9.CrossRefGoogle Scholar
  39. 39.
    Matsukawa Y, Funahashi Y, Takai S, et al. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER study). J Urol. 2017;197:452–8.CrossRefGoogle Scholar
  40. 40.
    Eisenhardt A, Schneider T, Cruz F. Oelke M Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies. World J Urol. 2014;32:1119–25.CrossRefGoogle Scholar
  41. 41.
    Montorsi F. Profile of silodosin. Eur Urol Suppl. 2010;9:491–5.CrossRefGoogle Scholar
  42. 42.
    McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–98.CrossRefGoogle Scholar
  43. 43.
    Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179:616–21.CrossRefGoogle Scholar
  44. 44.
    Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123–31.CrossRefGoogle Scholar
  45. 45.
    Matsukawa Y, Takai S, Funahashi Y, et al. Effects of withdrawing α1-blocker from combination therapy with α1-blocker and 5α-reductase inhibitor in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective and comparative trial using urodynamics. J Urol. 2017;198:905–12.CrossRefGoogle Scholar
  46. 46.
    Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011;65:487–507.CrossRefGoogle Scholar
  47. 47.
    Matsukawa Y, Takai S, Funahashi Y, Kato M, Yamamoto T, Gotoh M. Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourol Urodyn. 2017;36:748–54.CrossRefGoogle Scholar
  48. 48.
    MacDiarmid SA, Hill LA, Volinn W, Hoel G. Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. Urology. 2010;75:520–5.CrossRefGoogle Scholar
  49. 49.
    Buono R, Briganti A, Freschi M, et al. Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostates. Eur J Pharmacol. 2014;744:42–51.CrossRefGoogle Scholar
  50. 50.
    Yoshida T, Kinoshita H, Shimada S, Taguchi M, Matsuda T. Comparison of silodosin monotherapy vs silodosin with tadalafil add-on therapy in patients with benign prostatic hyperplasia. Urology. 2017;106:159.Google Scholar
  51. 51.
    Canda AE, Turna B, Cinar GM, Nazli O. Physiology and pharmacology of the human ureter: basis for current and future treatments. Urol Int. 2007;78:289–98.CrossRefGoogle Scholar
  52. 52.
    Park HK, Choi EY, Jeong BC, Kim HH, Kim BK. Localizations and expressions of alpha-1A, alpha-1B and alpha-1D adrenoceptors in human ureter. Urol Res. 2007;35:325–9.CrossRefGoogle Scholar
  53. 53.
    Kobayashi S, Tomiyama Y, Maruyama K, Hoyano Y, Yamazaki Y, Kusama H. Effects of four different alpha(1)-adrenoceptor antagonists on alpha-adrenoceptor agonist-induced contractions in isolated mouse and hamster ureters. J Smooth Muscle Res. 2009;45:187–95.CrossRefGoogle Scholar
  54. 54.
    Rajpathy J, Aswathaman K, Sinha M, Subramani S, Gopalakrishnan G, Kekre NS. An in vitro study on human ureteric smooth muscle with the alpha1-adrenoceptor subtype blocker, tamsulosin. BJU Int. 2008;102:1743–5.CrossRefGoogle Scholar
  55. 55.
    Davenport K, Timoney AG, Keeley FX Jr. Effect of smooth muscle relaxant drugs on proximal human ureteric activity in vivo: a pilot study. Urol Res. 2007;35:207–13.CrossRefGoogle Scholar
  56. 56.
    Sasaki S, Tomiyama Y, Kobayashi S, Kojima Y, Kubota Y, Kohri K. Characterization of α1-adrenoceptor subtypes mediating contraction in human isolated ureters. Urology. 2011;77(762):e13–7.Google Scholar
  57. 57.
    Kobayashi S, Tomiyama Y, Hoyano Y, et al. Effects of silodosin and naftopidil on the distal ureter and cardiovascular system in anesthetized dogs: comparison of potential medications for distal ureteral stone passage. J Urol. 2010;183:357–61.CrossRefGoogle Scholar
  58. 58.
    Villa L, Buono R, Fossati N, Rigatti P, Montorsi F, Benigni F, Hedlund P. Effects by silodosin on the partially obstructed rat ureter in vivo and on human and rat isolated ureters. Br J Pharmacol. 2013;169:230–8.CrossRefGoogle Scholar
  59. 59.
    Tsuzaka Y, Matsushima H, Kaneko T, et al. Naftopidil vs silodosin in medical expulsive therapy for ureteral stones: a randomized controlled study in Japanese male patients. Int J Urol. 2011;18:792–5.CrossRefGoogle Scholar
  60. 60.
    Itoh Y, Okada A, Yasui T, et al. Efficacy of selective alpha1A adrenoceptor antagonist silodosin in the medical expulsive therapy for ureteral stones. Int J Urol. 2011;18:672–4.PubMedGoogle Scholar
  61. 61.
    Itoh Y, Okada A, Yasui T, et al. Administration of the selective alpha 1A-adrenoceptor antagonist silodosin facilitates expulsion of size 5–10 mm distal ureteral stones, as compared to control. Int Urol Nephrol. 2013;45:675–8.CrossRefGoogle Scholar
  62. 62.
    Sur RL, Shore N, L’Esperance J, et al. Silodosin to facilitate passage of ureteral stones: a multi-institutional, randomized, double-blinded, placebo-controlled trial. Eur Urol. 2015;67(9):59–64.Google Scholar
  63. 63.
    Kumar S, Jayant K, Agrawal MM, Singh SK, Agrawal S, Parmar KM. Role of tamsulosin, tadalafil, and silodosin as the medical expulsive therapy in lower ureteric stone: a randomized trial (a pilot study). Urology. 2015;85:59–63.CrossRefGoogle Scholar
  64. 64.
    Nickel JC, O’Leary MP, Lepor H, et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double-blind, placebo controlled study. J Urol. 2011;186:125–31.CrossRefGoogle Scholar
  65. 65.
    Shirakawa T, Haraguchi T, Shigemura K, et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. Int J Urol. 2013;20:903–10.CrossRefGoogle Scholar
  66. 66.
    Miyakita H, Yokoyama E, Onodera Y, et al. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia. Int J Urol. 2010;17(10):869–75.CrossRefGoogle Scholar
  67. 67.
    Shimizu N, Minami T, Sugimoto K, et al. Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study. World J Urol. 2014;32:1423–32.CrossRefGoogle Scholar
  68. 68.
    Tsumura H, Satoh T, Ishiyama H, et al. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial. Int J Radiat Oncol Biol Phys. 2011;81:e385–92.CrossRefGoogle Scholar
  69. 69.
    Kumar S, Tiwari DP, Ganesamoni R, Singh SK. Prospective randomized placebo-controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology. 2013;82:171–5.CrossRefGoogle Scholar
  70. 70.
    Hagiwara K, Koie T, Iwamura H, et al. Efficacy and safety of silodosin and dutasteride combination therapy in acute urinary retention due to benign prostatic hyperplasia: a single-arm prospective study. Biomed Res Int. 2016;2016:4975851.CrossRefGoogle Scholar
  71. 71.
    Agency. EM. CHMP ASSESSMENT REPORT FOR Silodyx. Doc.Ref.: EMA/72316/2010. Procedure no. EMEA/H/C/001209. 2010 [cited] Accessed 13 Mar 2018.
  72. 72.
    Michel MC. Alpha1-adrenoceptors and ejaculatory function. Br J Pharmacol. 2007;152:289–90.CrossRefGoogle Scholar
  73. 73.
    Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol. 2006;176:1529–33.CrossRefGoogle Scholar
  74. 74.
    Tatemichi S, Kobayashi K, Yokoi R, et al. Comparison of the effects of four α1-adrenoceptor antagonists on ejaculatory function in rats. Urology. 2012;80(486):e9–16.Google Scholar
  75. 75.
    Kobayashi K, Masumori N, Hisasue S, et al. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers. J Sex Med. 2008;5(9):2185–90.CrossRefGoogle Scholar
  76. 76.
    Roehrborn CG, Kaplan SA, Lepor H, Volinn W. Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis. 2011;14:143–8.CrossRefGoogle Scholar
  77. 77.
    Homma Y, Kawabe K, Takeda M, Yoshida M. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology. 2010;76:1446–50.CrossRefGoogle Scholar
  78. 78.
    Gacci M, Ficarra V, Sebastianelli A. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11:1554–66.CrossRefGoogle Scholar
  79. 79.
    Capogrosso P, Serino A, Ventimiglia E, et al. Effects of silodosin on sexual function—realistic picture from the everyday clinical practice. Andrology. 2015;3:1076–81.CrossRefGoogle Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2018

Authors and Affiliations

  • Luca Villa
    • 1
    Email author
  • Paolo Capogrosso
    • 1
  • Umberto Capitanio
    • 1
  • Alberto Martini
    • 1
    • 2
  • Alberto Briganti
    • 1
    • 2
  • Andrea Salonia
    • 1
    • 2
  • Francesco Montorsi
    • 1
    • 2
  1. 1.Division of Experimental Oncology/Unit of Urology, URIIRCCS Ospedale San RaffaeleMilanItaly
  2. 2.Università Vita-Salute San RaffaeleMilanItaly

Personalised recommendations